Compare Amylx Pharmaceuticals Inc (AMLX) vs Coursera Inc (COUR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Coursera Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Coursera Inc trades at $5.65 (market cap $1.52B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | COUR | |
|---|---|---|
Market Cap | $2.53B | $1.52B |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $12.20 |
52-Week Low | $7.82 | $5.09 |
Enterprise Value | $2.28B | $778.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Coursera (COUR) trades at $5.81, up 4.5% with bullish technical signals and strong analyst support. The company shows improving revenue growth ($757.5M in 2025, projected to $885M in 2026) but remains unprofitable with negative margins. Recent Q2 2026 earnings beat expectations with $0.17 EPS versus $0.10 estimate, while the company made a strategic $100M investment in AI education startup LearnVector.
The stock offers 32% upside to consensus price target of $7.70, supported by 53% buy ratings, but faces execution risks from persistent losses and competitive pressures in online education. Revenue growth trajectory and cost management will be critical for valuation improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
